Hurthle cell carcinoma: A population-level analysis of 3311 patients

Cancer

Volumn 119, Issue 3, 2013, Pages 504-511

  Goffredo, Paolo ^a   Roman, Sanziana A ^b   Sosa, Julie A ^b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

compliance; differentiated thyroid cancer; guidelines; Hurthle cell carcinoma; Surveillance, Epidemiology, and End Results; survival

Indexed keywords

RADIOISOTOPE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY IMPLANT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; COMPARATIVE STUDY; DEMOGRAPHY; DIFFERENTIATED THYROID CANCER; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; DISEASE SURVEILLANCE; FEMALE; HISTOPATHOLOGY; HUMAN; HURTHLE CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MARRIAGE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; POPULATION; SEER PROGRAM; SURVIVAL ANALYSIS; THYROID NEOPLASMS; UNITED STATES; YOUNG ADULT;

EID: 84872912002     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27770     Document Type: Article

References (25)

1. Ahmed M, Bin Yousef H, Greer W, et al. Hurthle cell neoplasm of the thyroid gland. ANZ J Surg. 2008; 78: 139-143.
2. Mills SC, Haq M, Smellie WJ, Harmer C,. Hurthle cell carcinoma of the thyroid: retrospective review of 62 patients treated at the Royal Marsden Hospital between 1946 and 2003. Eur J Surg Oncol. 2009; 35: 230-234.
3. Phitayakorn R, McHenry CR,. Follicular and Hurthle cell carcinoma of the thyroid gland. Surg Oncol Clin North Am. 2006; 15: 603-623, ix-x.
4. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2009; 19: 1167-1214.
5. Guerrero MA, Suh I, Vriens MR, et al. Age and tumor size predicts lymph node involvement in Hurthle cell carcinoma. J Cancer. 2010; 1: 23-26.
6. Bishop JA, Wu G, Tufano RP, Westra WH,. Histological patterns of locoregional recurrence in Hurthle cell carcinoma of the thyroid gland. Thyroid. 2012; 22: 690-694.
7. Barnabei A, Ferretti E, Baldelli R, Procaccini A, Spriano G, Appetecchia M,. Hurthle cell tumours of the thyroid. Personal experience and review of the literature. Acta Otorhinolaryngol Ital. 2009; 29: 305-311.
8. Bhattacharyya N,. Survival and prognosis in Hurthle cell carcinoma of the thyroid gland. Arch Otolaryngol Head Neck Surg. 2003; 129: 207-210.
9. Haigh PI, Urbach DR,. The treatment and prognosis of Hurthle cell follicular thyroid carcinoma compared with its non-Hurthle cell counterpart. Surgery 138: 1152-1157, 2005; discussion 1157-1158.
10. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Available at: http://seer.cancer.gov/. Accessed April 17, 2012.
11. Fritz A, Percy C, Jack A, et al. eds. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
12. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Index of cancer registries. Available at: http://seer.cancer. gov/registries/index.html. Accessed April 19, 2009.
13. National Cancer Institute. Staging information for thyroid cancer. Available at: http://cancer.gov/cancertopics/pdq/treatment/thyroid/ HealthProfessional/page3. Accessed April 30, 2012.
14. Montone KT, Baloch ZW, LiVolsi VA,. The thyroid Hurthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review. Arch Pathol Lab Med. 2008; 132: 1241-1250.
15. Dahl LD, Myssiorek D, Heller KS,. Hurthle cell neoplasms of the thyroid. Laryngoscope. 2002; 112: 2178-2180.
16. Trimboli P, Ulisse S, Graziano FM, et al. Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years. Thyroid. 2006; 16: 1151-1155.
17. Chow SM, Law SC, Au SK, et al. Changes in clinical presentation, management and outcome in 1348 patients with differentiated thyroid carcinoma: experience in a single institute in Hong Kong, 1960-2000. Clin Oncol (R Coll Radiol). 2003; 15: 329-336.
18. Roman S, Lin R, Sosa JA,. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006; 107: 2134-2142.
19. Cooper DS, Schneyer CR,. Follicular and Hurthle cell carcinoma of the thyroid. World J Surg. 2001; 25: 1160-1163.
20. Foote RL, Brown PD, Garces YI, McIver B, Kasperbauer JL,. Is there a role for radiation therapy in the management of Hurthle cell carcinoma? Int J Radiat Oncol Biol Phys. 2003; 56: 1067-1072.
21. Besic N, Vidergar-Kralj B, Frkovic-Grazio S, Movrin-Stanovnik T, Auersperg M,. The role of radioactive iodine in the treatment of Hurthle cell carcinoma of the thyroid. Thyroid. 2003; 13: 577-584.
22. Famakinwa OM, Roman SA, Wang TS, Sosa JA,. ATA practice guidelines for the treatment of differentiated thyroid cancer: where they followed in the United States? Am J Surg. 2010; 199: 189-198.
23. Wang L, Wilson SE, Stewart DB, Hollenbeak CS,. Marital status and colon cancer outcomes in US Surveillance, Epidemiology and End Results registries: does marriage affect cancer survival by gender and stage? Cancer Epidemiol. 2011; 35: 417-422.
24. National Cancer Institute; SEER: Surveillance, Epidemiology, and End Results Program. SEER Quality Improvement. Available at: http://seer.cancer.gov/ qi/. Accessed April 26, 2012.
25. Harlan LC, Hankey BF,. The Surveillance, Epidemiology, and End-Results Program database as a resource for conducting descriptive epidemiologic and clinical studies. J Clin Oncol. 2003; 21: 2232-2233.